DeutschNewstral
Article
jdsupra.com on 2020-05-08 03:12
Rough Seas for COVID-19 Serology Tests Lead to Course Correction by FDA
Related news
- FDA Increases Scrutiny of COVID-19 Serology Tests: What Commercial Manufacturers Need to Knowjdsupra.com
- Rough Seas for the Cruise Industryjdsupra.com
- FDA resumes enforcement relating to laboratory developed testsjdsupra.com
- FDA Continues to Accelerate Availability of COVID-19 Testsjdsupra.com
- FDA Updates Policy for Antibody Tests for COVID-19: New Requirements for Manufacturersjdsupra.com
- Recent Amendments to the Shipping Act: A Course Correction, Not a Sea Changejdsupra.com
FDA approves first serology test for coronavirusNew York Post- FDA Confirms That At-Home Collection Kits Are Not Authorized for Use with COVID-19 Testsjdsupra.com
- FDA permits waivers of some REMS-required laboratory tests, imaging studies due to COVID-19jdsupra.com
- FDA Releases Biosimilars Action Planjdsupra.com
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- FDA Continues to Approve Biosimilarsjdsupra.com
- FDA Removes Certain Serology/Antibody Tests From the Marketjdsupra.com
- FDA Publishes Biosimilars Action Plan (BAP)jdsupra.com
- FDA Guidance on DSCSA Product Identifier Requirementsjdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- FDA Takes Aggressive Action Against CBD Productsjdsupra.com
- FDA Publishes List Of Required FSVP Recordsjdsupra.com
- FDA to Unveil Biosimilars Action Plan (BAP)jdsupra.com
- BakerHostetler FDA and Pharmacy Weekly Digestjdsupra.com